PlateletBio Names Derek Adams, Ph.D., as Chief Operating OfficerZiad PlateletBio, a private cell therapy company focused on developing a suite of allogeneic cell therapeutics based on a platform of platelet-like cells (PLCs), today announced that Derek Adams has joined the company as its Chief Operating Officer (COO). Read more >>
What I Learned Running A Biotech During The PandemicZiad As I biked home from PlateletBio’s new offices in Watertown, MA, last March, I was excited about all we planned to accomplish in 2020. We had recently raised more than $80 million in venture funding and non-dilutive grants, built our own lab, and had ambitious plans for 2020. Read more >>
Innovation Project Spotlight November 2020Ziad A donor-independent, on-demand emergency source of platelets is needed to serve as a medical countermeasure (MCM) for mass casualty incidents. See how BARDA is investing in Platelet Biogenesis’s advanced manufacturing platform to develop synthetic platelet-like cells. Read more >>
Advancing Platelet-Based Therapeutics for PatientsZiad Platelet BioGenesis (PBG) reports that it is working with the Canadian Centre for Commercialization of Regenerative Medicine (CCRM) and GE Healthcare Life Sciences to develop customized media formulations that will enable efficient differentiation of stem cells to platelet-based treatments, thereby avoiding the reliance on blood donors in the future. Read more >>
New project to advance platelet-based therapeutics for patientsZiad There is a chronic global shortage of platelets to treat patients who are actively bleeding due to trauma or surgery, those undergoing treatments for cancer, or those with low platelet counts due to a variety of conditions – essentially anyone who needs to prevent life-threatening bleeding. Platelet BioGenesis (PBG) is working with CCRM and GE Healthcare Life Sciences to develop customized media formulations that will enable efficient differentiation of stem cells to platelet-based therapeutics, thereby avoiding the reliance on blood...
Platelet BioGenesis Receives $2.3 Million Award from the Medical Technology Enterprise Consortium to Accelerate Development of Donor-Independent Platelet ProductionZiad Platelet Biogenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+™) and genetically engineered platelet-based therapeutics, announced today it received an award of $2.3 million from the Medical Technology Enterprise Consortium (MTEC) – a 501(c)(3) biomedical technology consortium collaborating with the U.S. Army Medical Research and Development Command (USAMRDC). Read more >>
September VC Funding Update: 54 Startups Raise More Than a Billion DollarsZiad The summer slump wore off in September with over 50 Boston startups raising north of a billion dollars in venture funding, including Platelet BioGenesis. Read more >>
New technology may aid emergency preparednessZiad The Department of Health and Human Services (HHS) has earmarked funds to aid the development of new technology that could bolster emergency preparedness by producing platelets outside the human body. If the two-year, $4.9 million agreement between HHS Biomedical Advanced Research and Development Authority (BARDA) and Platelet BioGenesis, Inc. (PBG) of Cambridge, Mass., produces the desired results, the technology would improve emergency preparedness by making additional blood products available to save lives during a radiological or nuclear emergency. Read more...